PBLSParabilis Medicines, Inc.
$24.47
$24.47
$22.7452 weeks$41.68
Price
End-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for PBLS today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$3.02B
1 yearn/a
5 yearsn/a
Parabilis Medicines, Inc. (PBLS) reported revenue of $148K in Q2-Q3 2026 (quarter ended Jun 30, 2026). That came with net loss of $98M.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 2, 2026On August 28, 2026, Parabilis Medicines, Inc. (the “Company”) and Fawzi Benzaghou, M.D., the Company’s Chief Medical Officer, mutually agreed that Dr. Benzaghou would transition from the Company effective as of September 30, 2026.Director or officer change · Form 8-K
- Aug 25, 2026On August 22, 2026, the Board of Directors (the “Board”) of Parabilis Medicines, Inc. (the “Company”) increased the number of directors of the Company to nine (9) and appointed Craig Tendler as a director of the Company to fill the newly created vacancy.Director or officer change · Form 8-K
- Aug 13, 2026Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry